Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
Japan Weighs Drug Cost Cut of around 400 Billion Yen in Off-Year Re-Pricing, Expanded Coverage Including Products with Smaller-than-Average Price Gap Too
To read the full story
Related Article
- MHLW Announces New Drug Prices for 1st Off-Year Revision in April
March 5, 2021
- Special Mitigation Margin for COVID-19 Up for Debate towards FY2022 Drug Price Revision: MHLW Bureau Chief
January 15, 2021
- Chuikyo OKs Revised NHI Pricing Rules for FY2021 Drug Re-Pricing
January 14, 2021
- Chuikyo OKs Outline of FY2021 Off-Year Re-Pricing; Only Market Price-Linked Rules to Be Applied
December 21, 2020
- Ministers Agree on 5%-Plus Price Discrepancy Line for Off-Year Re-Pricing; 59% Coverage for Innovative Meds, 88% for LLPs, 83% for Gx
December 18, 2020
- Govt Settles on Discrepancy Rate Threshold of “Above 5%” for Off-Year Drug Re-Pricing, 430 Billion Yen Reduction, 60% Coverage for Innovative Meds
December 17, 2020
- Japan Govt Eyes 4-6% Price Discrepancy Threshold for Off-Year Drug Re-Pricing
December 16, 2020
- Chuikyo Healthcare Rep Wants Off-Year Re-Pricing Threshold Set at 2 Times-Plus Average Price Gap, Payers Want Further Estimates for Larger Product Coverage
December 14, 2020
- Chuikyo Healthcare Reps Urge Minimal Scope for Off-Year Re-Pricing, Payers Grumble over Generic-Heavy Coverage
December 10, 2020
- MHLW Estimates: Off-Year Re-Pricing with Average Price Gap Threshold Likely to Hit 8,700 Products, Save 360 Billion Yen
December 9, 2020
REGULATORY
- MHLW Plans Disposal of COVID-19 Antibody Meds in Government Stock
July 26, 2024
- HeartSheet’s Conditional Approval to Be Withdrawn as Early as August
July 26, 2024
- LDP Policy Panel OKs FY2025 Budget Guidelines, Lower Cap Likely for “Natural Increase”
July 24, 2024
- Health Minister Hopes to Tap US Insights to Foster Japan Ecosystem
July 24, 2024
- MHLW Seeks Input to Gird for Summer Outbreaks, FPMAJ Ready to Ask for Ramp-Up
July 23, 2024
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…